Opinion|Videos|January 13, 2025
Patient Case: AE Management in Practice With 1L IV Amivantamab
Panelists discuss practical insights and learning opportunities through interactive examination of a patient case.
Advertisement
Video content above is prompted by the following:
- Please present slides with patient case details and moderate brief discussion.
Advertisement
Related to this article
For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.
In a randomized trial, 73% of relatives offered navigation completed genetic testing within 6 months vs 51% of those who received a family letter.
In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient end-stage hematology care.
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Metastatic Breast Cancer: An NP and a Nurse-Patient on Hope and Honesty
2
Oral Vitamin C Misses Primary End Point in CCUS but Shows Survival Signal
3
Breast Cancer Awareness: An APN on Personalized Care and Survivorship
4
Understanding Opdivo Qvantig® (nivolumab and hyaluronidase-nvhy): A Cancer Treatment with A Faster Delivery*
5